Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The efficacy and safety of taxane therapy after discontinuation of nivolumab therapy in Japanese patients with advanced or recurrent esophageal cancer:a retrospective observational study (AFTER NIVO ESO Study)

Next Previous
Trial Profile

The efficacy and safety of taxane therapy after discontinuation of nivolumab therapy in Japanese patients with advanced or recurrent esophageal cancer:a retrospective observational study (AFTER NIVO ESO Study)

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Nivolumab (Primary) ; Paclitaxel (Primary)
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms AFTER NIVO ESO
  • Sponsors Bristol-Myers Squibb; Ono Pharmaceutical

Most Recent Events

  • 25 Oct 2021 Status changed from recruiting to active, no longer recruiting.
  • 10 Mar 2021 Status changed from not yet recruiting to recruiting.
  • 28 Oct 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top